KDR and renal carcinoma: Cabozantinib (Cabometyx, Cometriq, a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2) and pazopanib (Votrient, an inhibitor of three VEGF receptors) are used to treat advanced renal carcinoma.